Next Phase Newsletter

A thesis-driven earliest stage firm looks to lead investments in early-stage companies that are pre-seed. The firm is currently investing out of their second fund of USD 67 million. The firm primarily participates in equity investments including SAFEs but will consider other types of capital structures as requested by a founder. The firm invests largely in companies based in the United States and Canada but will also consider Europe and Latin America.

The firm is primarily interested in investing in companies in the digital health, diagnostics, and medical technology sectors with a focus in platform technologies. The firm will not consider investments in medical device companies. However, the firm will consider therapeutics with a platform technology component. The firm will only invest in technologies that are still pre-clinical and in development. The firm is disease agnostic and will consider companies across all indications including orphan diseases.

The firm will work with experienced and inexperienced management teams. The firm looks to invest in founders who are dedicated to their technology and their company. The firm is an active investor and will take an observer board seat as determined on a case-by-case basis. The firm prefers to act as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single family office representing USA-based family interests is very flexible in terms of investment size, but are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. Currently, the firm is investing only in companies based in North America.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. Currently, of particular interest are optical or sound-based technologies, devices that supplant drug use, orthopedics, gene/nucleic acid-based therapies, immuno-oncology and therapies correcting or treating loss of senses.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor. The firm is looking for companies that have already raised seed financing and have received allowance of claims by the USPTO.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in the USA. With about USD 600 million in assets under management, the firm looks to participate in pre-seed to pre-IPO funding. The firm launched a second fund expects to complete fundraising by Q2 2023. The firm will typically make between 15 and 20 new investments per year and will typically make follow up investments in existing portfolio companies. Typical investments range between USD 100 thousand and USD 30 million. The firm will utilize various capital structures as determined on a case-by-case basis including equity investments debt, convertible loans, and SAFEs. The firm invests primarily in companies in the Boston area.

The firm will make investments across all modalities within the medical devices, diagnostics, and digital health sectors. The firm has made and will consider investments in therapeutics as well but prefers to focus on platform technologies. The firm will invest in therapeutics that are pre-NDA as well as medical and diagnostic technology that is in development and clinical. The firm will invest in all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will consider companies across all indications.

The firm will work with both experienced and inexperienced management teams but tends to avoid management teams led by a journeyman CEO. The firm will participate as a lead investor, co-investor, and follow-on investor. The firm will take an active board seat if acting as the lead investor but tends to take a board observer seat if acting as a co-investor. The firm will not take any board seat if acting as a follow-on investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital firm is focused on early stage investment to support founders and their teams advance healthcare solutions. The team originated at a medical device company that has worked with researchers and physicians for more than 50 years to develop more effective tools. The firm makes initial investments in pre-seed and seed rounds (with reserve to follow in A rounds) as a dedicated partner working closely with startups to advance technologies and build companies. Initial investment ranges from $100k-$1M. The firm has a global presence and is open to early-stage companies from around the world.

The firm’s investment focus is digital solutions to improving healthcare. The firm is open to investing in companies across all stages of development.

The firm has no strict requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

One of the earliest venture capital funds active in Greater China is the proprietary venture capital and private equity arm of a world’s leading asset management organization with operations around the globe. Since inception, the firm has developed a broad footprint across Asia, with offices in Beijing, Shanghai, Hong Kong, Delhi, Mumbai and Tokyo. The firm specializes in green-field, early and growth stage investments.

Within life sciences, the firm works on a wide range of technology sectors including therapeutics, medical devices, diagnostics, biotech R&D services, healthcare IT, and healthcare services. The firm is very opportunistic in terms of subsectors and indications but historically has been active in biosimilars and biotech R&D. The firm evaluates technologies based on two main criteria: meaningful impact on human health; bold and innovative ideas. The firm has no specific preference in the investment stage. However, the firm generally invests in earlier stage for therapeutics and R&D and later stage for medical devices, but seeds have been done with exceptional founding teams.

The firm is seeking companies with a strong and experienced management team. The firm is flexible when it comes to post-investment board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Corporate venture arm of a large company has set up their fund with $100M to invest each year, with a portion of that going to investments in the life sciences. Within the life sciences, the firm is looking for investments that are both financial and strategic, and will only consider companies that can make use of the parent company’s expertise, or those that align with new strategic areas of interest. The firm is interested in companies with technologies in diagnostic, imaging, omics tools and pharmaceutical manufacturing processes. The firm invests globally, and will consider companies from prototype stage and on. The firm mostly invests in companies at Series B and later, but will consider Series A opportunities as well, and will invest between $0.5-7M per round.

The firm is interested in technologies that can make use of the parent company’s expertise in semiconductors, display, and material engineering. Examples of potential areas of interest include imaging technologies that adapt the company’s inspection ability to detect defects on a nano scale, diagnostics platforms making use of semiconductors or other novel materials as part of their instrumentation and devices, or companies that can adapt the parent company’s advanced manufacturing to control chemical deposition and use different time release formulations to advance drug delivery techniques.

The firm can lead or co-invest, but will take a board observer seat when co-investing, and a board seat when acting as a lead. The firm looks to invest in companies where the expertise of the parent company is applicable to moving the technology forward.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A specialized US venture capital firm under a large China-headquartered company conducts business with a sister company as one group.  The firm has an additional virtual office in USA. The firm is actively seeking investment opportunities from early stage to pre-IPO rounds.  The average size of investment is ~ $5M.  The firm has invested in 17 US & Canada companies since 2016.  The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies.  The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA.  The firm is open to any phases in medical devices and therapeutics. However, the firm will invest in private companies only.

The firm has no specific requests on the management team.  The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.